-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Pyruvate Kinase Activators: Targeting Red Cell Metabolism in Thalassemia

Program: Education Program
Session: Energizing the Red Cell: Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias
Hematology Disease Topics & Pathways:
Research, clinical trials, adult, Non-Biological therapies, Clinical Research, Thalassemia, Hemoglobinopathies, Diseases, Therapies, Pharmacology, Study Population, Human
Monday, December 11, 2023, 10:30 AM-11:45 AM

Kevin H.M. Kuo, MD, FRCPC, MSc

Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, ON, Canada; Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Division of Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada

Disclosures: Kuo: Bioverativ/Sanofi/Sangamo: Membership on an entity's Board of Directors or advisory committees; Novo/Nordisk: Consultancy, Honoraria; Pfizer: Consultancy; Forma Therapeutics: Consultancy; Bristol Myers Squibb: Consultancy, Honoraria; Alexion Pharmaceuticals: Consultancy; Agios Pharmaceuticals: Consultancy, Research Funding; Vertex Pharmaceuticals: Consultancy.

See more of: Energizing the Red Cell: Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias
See more of: Education Program
<< Previous Presentation | Next Presentation